Does CARFILZOMIB Cause Thrombophlebitis superficial? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Thrombophlebitis superficial have been filed in association with CARFILZOMIB (KYPROLIS). This represents 0.0% of all adverse event reports for CARFILZOMIB.
6
Reports of Thrombophlebitis superficial with CARFILZOMIB
0.0%
of all CARFILZOMIB reports
1
Deaths
0
Hospitalizations
How Dangerous Is Thrombophlebitis superficial From CARFILZOMIB?
Of the 6 reports, 1 (16.7%) resulted in death.
Is Thrombophlebitis superficial Listed in the Official Label?
Yes, Thrombophlebitis superficial is listed as a known adverse reaction in the official FDA drug label for CARFILZOMIB.
What Other Side Effects Does CARFILZOMIB Cause?
Plasma cell myeloma (2,238)
Off label use (2,120)
Death (1,442)
Thrombocytopenia (1,265)
Fatigue (1,048)
Pneumonia (1,016)
Pyrexia (969)
Anaemia (910)
Dyspnoea (881)
Neutropenia (874)
What Other Drugs Cause Thrombophlebitis superficial?
DROSPIRENONE\ETHINYL ESTRADIOL (160)
LENALIDOMIDE (121)
ETHINYL ESTRADIOL\ETONOGESTREL (93)
RIVAROXABAN (82)
YAZ (78)
YASMIN (65)
TESTOSTERONE (62)
HUMAN IMMUNOGLOBULIN G (43)
ADALIMUMAB (40)
CAPECITABINE (29)
Which CARFILZOMIB Alternatives Have Lower Thrombophlebitis superficial Risk?
CARFILZOMIB vs CARGLUMIC ACID
CARFILZOMIB vs CARIPRAZINE
CARFILZOMIB vs CARISOPRODOL
CARFILZOMIB vs CARMUSTINE
CARFILZOMIB vs CARTEOLOL